This was a prospective, single-center, open-label, pilot study, in which 12 patients with mild-to-severe Alzheimer’s disease were administered etanercept, 25-50 mg, weekly by perispinal administration for six months.
Complete the Request a Consultation Form or call +1 (561) 353-9707 to request a phone or in-office consultation with an INR medical provider.
Form HereEdward Tobinick, M.D., the founder and Director of the Institute of Neurological Recovery, invented the remarkable groundbreaking perispinal etanercept treatment for stroke and chronic brain injury in 2010. Now, in 2024, there have been thousands of individuals with chronic stroke symptoms successfully treated by Dr. Tobinick. Dr. Tobinick has now treated individuals from every state in the U.S. and from 102 countries.
In October 2018, the Australian Government announced their designation of substantial funding to study perispinal etanercept(PSE) for treatment of stroke. On January 3, 2020 a university, double-blind, randomized, placebo-controlled, clinical trial confirmed the efficacy of perispinal etanercept for treatment of chronic neurological symptoms after stroke. Dr. Tobinick was instrumental in the design of the university study.
Dr. Tobinick accepts patients for treatment from all parts of the world, and has treated patients from every populated continent of the world.
Scientific articles from hundreds of academic scientists around the world have cited Dr. Tobinick's scientific publications.
The Institute of Neurological Recovery® (INR®). Two decades of pioneering discoveries in medicine. The INR utilizes the pioneering, patented perispinal etanercept (PSE) off-label treatment method invented by its founder and Medical Director, Edward Tobinick, M.D. The contents of this website, including text, images, and videos are ©2024 INR PLLC, all rights reserved. Reproduction in whole or part prohibited. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8,900,583; Australian patents 758523 and 2011323616 B2, Canadian patent 2,811,948, European patents ES2620749 (T3), EP 2 635 283 B1 and multiple European counterparts (Germany, France, Spain, Italy, Denmark, Sweden, Norway, the Netherlands, Belgium, Switzerland, Ireland, UK), all assigned to TACT IP LLC.
Privacy Policy | Login
Institute of Neurological Recovery – Stroke
1877 S. Federal Hwy., Suite 110 • Boca Raton, FL 33432
+1 (561) 353-9707